Clinical study of recombinant human endostatin in deferent time combined with paclitaxel and cisplatin in treatment of advanced none-small cell lung cancer

Trial Profile

Clinical study of recombinant human endostatin in deferent time combined with paclitaxel and cisplatin in treatment of advanced none-small cell lung cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Endostatin (Primary) ; Cisplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 29 Jul 2014 Status changed from not yet recruiting to completed as reported by Chinese Clinical Trial Register
    • 25 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top